Acne Medication Market By Therapeutic Class (Retinoid, Antibiotic, Salicylic Acid, Benzoyl Peroxide, Other medications), By Formulation (Topical Medication, Oral Medication), By Type (Prescription Medicine, Over-the-counter medicines), By Acne Type (Non-inflammatory acne, Inflammatory acne), By Distribution Channel (Retail Store, Pharmacy and Drug Store, E-Commerce): Global Opportunity Analysis and Industry Forecast, 2024-2035

April 2024 | 280 pages | ID: A92C6A8E4B44EN
Allied Market Research

Abstracts

The global acne medication market was valued at $13.4 billion in 2023, and is estimated t%li%reach $24.2 billion by 2035, growing at a CAGR of 5.1% from 2024 t%li%2035. Acne is a common skin condition characterized by the formulation of pimples, blackheads, whiteheads, cysts, or nodules, usually appearing on the face, chest, back, or shoulders. It occurs when hair follicles become clogged with oil and dead skin cells, leading t%li%the proliferation of bacteria and inflammation. Several factors contribute t%li%the development of acne, including hormonal fluctuations, genetics, excess oil production, bacteria, and certain medications or cosmetics. The treatment includes retinoid, antibiotic, salicylic acid, benzoyl peroxide, and other medications.The acne medication market is expected t%li%register significant growth due t%li%rise in incidences of acne and unhealthy diet. Acne is one of the most common skin conditions globally, affecting individuals of all ages, genders, and ethnicities. Its prevalence has been steadily increasing over the years, driven by factors such as hormonal changes, environmental influences, dietary habits, and lifestyle choices. According t%li%a 2023 article by the National Library of Medicine, acne vulgaris is commonly observed in adolescents and young adults. Prevalence rate of acne vulgaris is estimated t%li%range from 35% t%li%over 90% among adolescents. Thus, rise in the prevalence of acne is expected t%li%drive the growth of the market.Furthermore, an unhealthy lifestyle serves as a significant driver for the acne medication market. Lifestyle factors such as poor dietary habits, high stress levels, inadequate sleep, and exposure t%li%environmental pollutants contribute t%li%the development and exacerbation of acne. Unbalanced diets high in refined sugars, processed foods, and dairy products can trigger hormonal fluctuations and increase sebum production, both of which are key factors in acne formulation. In addition, elevated stress levels stimulate the release of stress hormones like cortisol, which can lead t%li%inflammation and exacerbate existing acne lesions. According t%li%a 2023 article by Anxiety and Depression Association of America, it was reported that Generalized Anxiety Disorder affects 6.8 million adults or 3.1% of the U.S. population. Furthermore, insufficient sleep disrupts the body's natural healing processes and weakens the immune system, making individuals more susceptible t%li%bacterial infections and inflammation associated with acne. Thus, the unhealthy lifestyle has resulted in growing incidence of acne resulting in increase in demand for acne medication.The acne medication market is segmented on the basis of therapeutic class, formulation, type, acne type, distribution channel, and region. By therapeutic class, the market is divided int%li%retinoid, antibiotic, salicylic acid, benzoyl peroxide, and others. By formulation, the market is classified int%li%topical and oral medication. By type, the market is distributed int%li%prescription medicine and over-the-counter medicines. By acne type, the market is distributed int%li%non-inflammatory acne and inflammatory acne. By distribution channel, the market is classified int%li%retail stores, pharmacy and drug stores, and e-commerce. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA)Major key players operating in the acne medication market are Bausch Health Companies Inc., Mayne Pharma Group Limited, Sun Pharmaceutical Industries Limited, Johnson and Johnson, GlaxoSmithKline Plc, Mylan N.V., Almirall Sa, Galderma S.A., Teva Pharmaceutical Industries Ltd., and Pfizer Inc. Key players have adopted acquisition as a key developmental strategy t%li%improve the product portfoli%li%of the acne medication market

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the acne medication market analysis from 2023 t%li%2035 t%li%identify the prevailing acne medication market opportunities.
• The market research is offered along with information related t%li%key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers t%li%enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the acne medication market segmentation assists t%li%determine the prevailing market opportunities.
• Major countries in each region are mapped according t%li%their revenue contribution t%li%the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global acne medication market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk t%li%the sales executive t%li%know more)
• Regulatory Guidelines
• Additional company profiles with specific t%li%client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

• Prescription Medicine
• Over-the-counter medicines

By Therapeutic Class

• Other medications
• Retinoid
• Type
• Topical and Combination retinoid
• Oral Retinoid
• Antibiotic
• Type
• Topical and Combination Antibiotics
• Oral Antibiotics
• Salicylic Acid
• Benzoyl Peroxide

By Acne Type

• Non-inflammatory acne
• Inflammatory acne

By Formulation

• Topical Medication
• Oral Medication

By Distribution Channel

• Retail Store
• Pharmacy and Drug Store
• E-Commerce

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• India
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA
• Key Market Players
• AbbVie Inc.
• Botanix Pharmaceuticals
• Galderma S.A.
• Bausch Health Companies Inc
• GlaxoSmithKline Plc.
• Bayer AG
• Kenvue Inc
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Mayne Pharma Group Limited.

Contents

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
  1.4.1. Primary research
  1.4.2. Secondary research
  1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
  3.2.1. Top impacting factors
  3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
  3.4.1. Drivers
  3.4.2. Restraints
  3.4.3. Opportunities

CHAPTER 4: ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

4.1. Overview
  4.1.1. Market size and forecast
4.2. Retinoid
  4.2.1. Key market trends, growth factors and opportunities
  4.2.2. Market size and forecast, by region
  4.2.3. Market share analysis by country
  4.2.4. Retinoid Acne Medication Market by Type
4.3. Antibiotic
  4.3.1. Key market trends, growth factors and opportunities
  4.3.2. Market size and forecast, by region
  4.3.3. Market share analysis by country
  4.3.4. Antibiotic Acne Medication Market by Type
4.4. Salicylic Acid
  4.4.1. Key market trends, growth factors and opportunities
  4.4.2. Market size and forecast, by region
  4.4.3. Market share analysis by country
4.5. Benzoyl Peroxide
  4.5.1. Key market trends, growth factors and opportunities
  4.5.2. Market size and forecast, by region
  4.5.3. Market share analysis by country
4.6. Other medications
  4.6.1. Key market trends, growth factors and opportunities
  4.6.2. Market size and forecast, by region
  4.6.3. Market share analysis by country

CHAPTER 5: ACNE MEDICATION MARKET, BY FORMULATION

5.1. Overview
  5.1.1. Market size and forecast
5.2. Topical Medication
  5.2.1. Key market trends, growth factors and opportunities
  5.2.2. Market size and forecast, by region
  5.2.3. Market share analysis by country
5.3. Oral Medication
  5.3.1. Key market trends, growth factors and opportunities
  5.3.2. Market size and forecast, by region
  5.3.3. Market share analysis by country

CHAPTER 6: ACNE MEDICATION MARKET, BY TYPE

6.1. Overview
  6.1.1. Market size and forecast
6.2. Prescription Medicine
  6.2.1. Key market trends, growth factors and opportunities
  6.2.2. Market size and forecast, by region
  6.2.3. Market share analysis by country
6.3. Over-the-counter medicines
  6.3.1. Key market trends, growth factors and opportunities
  6.3.2. Market size and forecast, by region
  6.3.3. Market share analysis by country

CHAPTER 7: ACNE MEDICATION MARKET, BY ACNE TYPE

7.1. Overview
  7.1.1. Market size and forecast
7.2. Non-inflammatory acne
  7.2.1. Key market trends, growth factors and opportunities
  7.2.2. Market size and forecast, by region
  7.2.3. Market share analysis by country
7.3. Inflammatory acne
  7.3.1. Key market trends, growth factors and opportunities
  7.3.2. Market size and forecast, by region
  7.3.3. Market share analysis by country

CHAPTER 8: ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

8.1. Overview
  8.1.1. Market size and forecast
8.2. Retail Store
  8.2.1. Key market trends, growth factors and opportunities
  8.2.2. Market size and forecast, by region
  8.2.3. Market share analysis by country
8.3. Pharmacy and Drug Store
  8.3.1. Key market trends, growth factors and opportunities
  8.3.2. Market size and forecast, by region
  8.3.3. Market share analysis by country
8.4. E-Commerce
  8.4.1. Key market trends, growth factors and opportunities
  8.4.2. Market size and forecast, by region
  8.4.3. Market share analysis by country

CHAPTER 9: ACNE MEDICATION MARKET, BY REGION

9.1. Overview
  9.1.1. Market size and forecast By Region
9.2. North America
  9.2.1. Key market trends, growth factors and opportunities
  9.2.2. Market size and forecast, by Therapeutic Class
  9.2.3. Market size and forecast, by Formulation
  9.2.4. Market size and forecast, by Type
  9.2.5. Market size and forecast, by Acne Type
  9.2.6. Market size and forecast, by Distribution Channel
  9.2.7. Market size and forecast, by country
    9.2.7.1. U.S.
      9.2.7.1.1. Market size and forecast, by Therapeutic Class
      9.2.7.1.2. Market size and forecast, by Formulation
      9.2.7.1.3. Market size and forecast, by Type
      9.2.7.1.4. Market size and forecast, by Acne Type
      9.2.7.1.5. Market size and forecast, by Distribution Channel
    9.2.7.2. Canada
      9.2.7.2.1. Market size and forecast, by Therapeutic Class
      9.2.7.2.2. Market size and forecast, by Formulation
      9.2.7.2.3. Market size and forecast, by Type
      9.2.7.2.4. Market size and forecast, by Acne Type
      9.2.7.2.5. Market size and forecast, by Distribution Channel
    9.2.7.3. Mexico
      9.2.7.3.1. Market size and forecast, by Therapeutic Class
      9.2.7.3.2. Market size and forecast, by Formulation
      9.2.7.3.3. Market size and forecast, by Type
      9.2.7.3.4. Market size and forecast, by Acne Type
      9.2.7.3.5. Market size and forecast, by Distribution Channel
9.3. Europe
  9.3.1. Key market trends, growth factors and opportunities
  9.3.2. Market size and forecast, by Therapeutic Class
  9.3.3. Market size and forecast, by Formulation
  9.3.4. Market size and forecast, by Type
  9.3.5. Market size and forecast, by Acne Type
  9.3.6. Market size and forecast, by Distribution Channel
  9.3.7. Market size and forecast, by country
    9.3.7.1. Germany
      9.3.7.1.1. Market size and forecast, by Therapeutic Class
      9.3.7.1.2. Market size and forecast, by Formulation
      9.3.7.1.3. Market size and forecast, by Type
      9.3.7.1.4. Market size and forecast, by Acne Type
      9.3.7.1.5. Market size and forecast, by Distribution Channel
    9.3.7.2. France
      9.3.7.2.1. Market size and forecast, by Therapeutic Class
      9.3.7.2.2. Market size and forecast, by Formulation
      9.3.7.2.3. Market size and forecast, by Type
      9.3.7.2.4. Market size and forecast, by Acne Type
      9.3.7.2.5. Market size and forecast, by Distribution Channel
    9.3.7.3. UK
      9.3.7.3.1. Market size and forecast, by Therapeutic Class
      9.3.7.3.2. Market size and forecast, by Formulation
      9.3.7.3.3. Market size and forecast, by Type
      9.3.7.3.4. Market size and forecast, by Acne Type
      9.3.7.3.5. Market size and forecast, by Distribution Channel
    9.3.7.4. Italy
      9.3.7.4.1. Market size and forecast, by Therapeutic Class
      9.3.7.4.2. Market size and forecast, by Formulation
      9.3.7.4.3. Market size and forecast, by Type
      9.3.7.4.4. Market size and forecast, by Acne Type
      9.3.7.4.5. Market size and forecast, by Distribution Channel
    9.3.7.5. Spain
      9.3.7.5.1. Market size and forecast, by Therapeutic Class
      9.3.7.5.2. Market size and forecast, by Formulation
      9.3.7.5.3. Market size and forecast, by Type
      9.3.7.5.4. Market size and forecast, by Acne Type
      9.3.7.5.5. Market size and forecast, by Distribution Channel
    9.3.7.6. Rest of Europe
      9.3.7.6.1. Market size and forecast, by Therapeutic Class
      9.3.7.6.2. Market size and forecast, by Formulation
      9.3.7.6.3. Market size and forecast, by Type
      9.3.7.6.4. Market size and forecast, by Acne Type
      9.3.7.6.5. Market size and forecast, by Distribution Channel
9.4. Asia-Pacific
  9.4.1. Key market trends, growth factors and opportunities
  9.4.2. Market size and forecast, by Therapeutic Class
  9.4.3. Market size and forecast, by Formulation
  9.4.4. Market size and forecast, by Type
  9.4.5. Market size and forecast, by Acne Type
  9.4.6. Market size and forecast, by Distribution Channel
  9.4.7. Market size and forecast, by country
    9.4.7.1. Japan
      9.4.7.1.1. Market size and forecast, by Therapeutic Class
      9.4.7.1.2. Market size and forecast, by Formulation
      9.4.7.1.3. Market size and forecast, by Type
      9.4.7.1.4. Market size and forecast, by Acne Type
      9.4.7.1.5. Market size and forecast, by Distribution Channel
    9.4.7.2. China
      9.4.7.2.1. Market size and forecast, by Therapeutic Class
      9.4.7.2.2. Market size and forecast, by Formulation
      9.4.7.2.3. Market size and forecast, by Type
      9.4.7.2.4. Market size and forecast, by Acne Type
      9.4.7.2.5. Market size and forecast, by Distribution Channel
    9.4.7.3. Australia
      9.4.7.3.1. Market size and forecast, by Therapeutic Class
      9.4.7.3.2. Market size and forecast, by Formulation
      9.4.7.3.3. Market size and forecast, by Type
      9.4.7.3.4. Market size and forecast, by Acne Type
      9.4.7.3.5. Market size and forecast, by Distribution Channel
    9.4.7.4. India
      9.4.7.4.1. Market size and forecast, by Therapeutic Class
      9.4.7.4.2. Market size and forecast, by Formulation
      9.4.7.4.3. Market size and forecast, by Type
      9.4.7.4.4. Market size and forecast, by Acne Type
      9.4.7.4.5. Market size and forecast, by Distribution Channel
    9.4.7.5. South Korea
      9.4.7.5.1. Market size and forecast, by Therapeutic Class
      9.4.7.5.2. Market size and forecast, by Formulation
      9.4.7.5.3. Market size and forecast, by Type
      9.4.7.5.4. Market size and forecast, by Acne Type
      9.4.7.5.5. Market size and forecast, by Distribution Channel
    9.4.7.6. Rest of Asia-Pacific
      9.4.7.6.1. Market size and forecast, by Therapeutic Class
      9.4.7.6.2. Market size and forecast, by Formulation
      9.4.7.6.3. Market size and forecast, by Type
      9.4.7.6.4. Market size and forecast, by Acne Type
      9.4.7.6.5. Market size and forecast, by Distribution Channel
9.5. LAMEA
  9.5.1. Key market trends, growth factors and opportunities
  9.5.2. Market size and forecast, by Therapeutic Class
  9.5.3. Market size and forecast, by Formulation
  9.5.4. Market size and forecast, by Type
  9.5.5. Market size and forecast, by Acne Type
  9.5.6. Market size and forecast, by Distribution Channel
  9.5.7. Market size and forecast, by country
    9.5.7.1. Brazil
      9.5.7.1.1. Market size and forecast, by Therapeutic Class
      9.5.7.1.2. Market size and forecast, by Formulation
      9.5.7.1.3. Market size and forecast, by Type
      9.5.7.1.4. Market size and forecast, by Acne Type
      9.5.7.1.5. Market size and forecast, by Distribution Channel
    9.5.7.2. Saudi Arabia
      9.5.7.2.1. Market size and forecast, by Therapeutic Class
      9.5.7.2.2. Market size and forecast, by Formulation
      9.5.7.2.3. Market size and forecast, by Type
      9.5.7.2.4. Market size and forecast, by Acne Type
      9.5.7.2.5. Market size and forecast, by Distribution Channel
    9.5.7.3. South Africa
      9.5.7.3.1. Market size and forecast, by Therapeutic Class
      9.5.7.3.2. Market size and forecast, by Formulation
      9.5.7.3.3. Market size and forecast, by Type
      9.5.7.3.4. Market size and forecast, by Acne Type
      9.5.7.3.5. Market size and forecast, by Distribution Channel
    9.5.7.4. Rest of LAMEA
      9.5.7.4.1. Market size and forecast, by Therapeutic Class
      9.5.7.4.2. Market size and forecast, by Formulation
      9.5.7.4.3. Market size and forecast, by Type
      9.5.7.4.4. Market size and forecast, by Acne Type
      9.5.7.4.5. Market size and forecast, by Distribution Channel

CHAPTER 10: COMPETITIVE LANDSCAPE

10.1. Introduction
10.2. Top winning strategies
10.3. Product mapping of top 10 player
10.4. Competitive dashboard
10.5. Competitive heatmap
10.6. Top player positioning, 2023

CHAPTER 11: COMPANY PROFILES

11.1. AbbVie Inc.
  11.1.1. Company overview
  11.1.2. Key executives
  11.1.3. Company snapshot
  11.1.4. Operating business segments
  11.1.5. Product portfolio
  11.1.6. Business performance
  11.1.7. Key strategic moves and developments
11.2. Botanix Pharmaceuticals
  11.2.1. Company overview
  11.2.2. Key executives
  11.2.3. Company snapshot
  11.2.4. Operating business segments
  11.2.5. Product portfolio
  11.2.6. Business performance
  11.2.7. Key strategic moves and developments
11.3. Galderma S.A.
  11.3.1. Company overview
  11.3.2. Key executives
  11.3.3. Company snapshot
  11.3.4. Operating business segments
  11.3.5. Product portfolio
  11.3.6. Business performance
  11.3.7. Key strategic moves and developments
11.4. Bausch Health Companies Inc
  11.4.1. Company overview
  11.4.2. Key executives
  11.4.3. Company snapshot
  11.4.4. Operating business segments
  11.4.5. Product portfolio
  11.4.6. Business performance
  11.4.7. Key strategic moves and developments
11.5. GlaxoSmithKline Plc.
  11.5.1. Company overview
  11.5.2. Key executives
  11.5.3. Company snapshot
  11.5.4. Operating business segments
  11.5.5. Product portfolio
  11.5.6. Business performance
  11.5.7. Key strategic moves and developments
11.6. Bayer AG
  11.6.1. Company overview
  11.6.2. Key executives
  11.6.3. Company snapshot
  11.6.4. Operating business segments
  11.6.5. Product portfolio
  11.6.6. Business performance
  11.6.7. Key strategic moves and developments
11.7. Kenvue Inc
  11.7.1. Company overview
  11.7.2. Key executives
  11.7.3. Company snapshot
  11.7.4. Operating business segments
  11.7.5. Product portfolio
  11.7.6. Business performance
  11.7.7. Key strategic moves and developments
11.8. Pfizer Inc.
  11.8.1. Company overview
  11.8.2. Key executives
  11.8.3. Company snapshot
  11.8.4. Operating business segments
  11.8.5. Product portfolio
  11.8.6. Business performance
  11.8.7. Key strategic moves and developments
11.9. Teva Pharmaceutical Industries Ltd.
  11.9.1. Company overview
  11.9.2. Key executives
  11.9.3. Company snapshot
  11.9.4. Operating business segments
  11.9.5. Product portfolio
  11.9.6. Business performance
  11.9.7. Key strategic moves and developments
11.10. Mayne Pharma Group Limited.
  11.10.1. Company overview
  11.10.2. Key executives
  11.10.3. Company snapshot
  11.10.4. Operating business segments
  11.10.5. Product portfolio
  11.10.6. Business performance
  11.10.7. Key strategic moves and developments